SG11201506211RA - Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate - Google Patents

Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate

Info

Publication number
SG11201506211RA
SG11201506211RA SG11201506211RA SG11201506211RA SG11201506211RA SG 11201506211R A SG11201506211R A SG 11201506211RA SG 11201506211R A SG11201506211R A SG 11201506211RA SG 11201506211R A SG11201506211R A SG 11201506211RA SG 11201506211R A SG11201506211R A SG 11201506211RA
Authority
SG
Singapore
Prior art keywords
methyl
pyrimidino
pyridino
fluorobenzyl
pyrazolo
Prior art date
Application number
SG11201506211RA
Inventor
Birgit Keil
Franz-Josef Mais
Winfried Joentgen
Alfons Grunenberg
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50137643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201506211R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA2807859A external-priority patent/CA2807859A1/en
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of SG11201506211RA publication Critical patent/SG11201506211RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201506211RA 2013-02-21 2014-02-18 Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate SG11201506211RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2807859A CA2807859A1 (en) 2013-02-21 2013-02-21 Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
CA2806895 2013-02-21
PCT/EP2014/053096 WO2014128109A1 (en) 2013-02-21 2014-02-18 Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate

Publications (1)

Publication Number Publication Date
SG11201506211RA true SG11201506211RA (en) 2015-09-29

Family

ID=50137643

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506211RA SG11201506211RA (en) 2013-02-21 2014-02-18 Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate

Country Status (23)

Country Link
US (5) US20150376184A1 (en)
EP (2) EP3760629A1 (en)
JP (1) JP6386478B2 (en)
KR (1) KR20150119871A (en)
CN (1) CN105102457A (en)
AP (1) AP2015008670A0 (en)
AU (1) AU2014220801A1 (en)
BR (1) BR112015019571A2 (en)
CA (1) CA2901636A1 (en)
CL (1) CL2015002304A1 (en)
CR (1) CR20150422A (en)
CU (1) CU20150092A7 (en)
DO (1) DOP2015000199A (en)
EA (1) EA201500852A1 (en)
HK (1) HK1217488A1 (en)
IL (1) IL240397A0 (en)
MX (1) MX2015010725A (en)
NI (1) NI201500110A (en)
PE (1) PE20151590A1 (en)
PH (1) PH12015501839A1 (en)
SG (1) SG11201506211RA (en)
TN (1) TN2015000361A1 (en)
WO (1) WO2014128109A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327107A (en) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 Preparation method of fluoroquinolone antibiosis medicine
CN104434845B (en) * 2014-11-12 2017-12-05 广东东阳光药业有限公司 A kind of solid pharmaceutical preparation for including the western croak of Leo
WO2016113415A1 (en) 2015-01-16 2016-07-21 Sandoz Ag Process for the preparation of riociguat essentially free from genotoxic impurities
US20180169095A1 (en) 2015-05-06 2018-06-21 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
DK3325013T4 (en) 2015-07-23 2023-10-16 Bayer Pharma AG STIMULATORS AND/OR ACTIVATORS OF THE SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF THE NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND AN ANGIOTENSIN AII ANTAGONIST AND THEIR USE
CN108463224A (en) 2015-12-14 2018-08-28 铁木医药有限公司 SGC stimulants are used for the application of gastrointestinal dysfunction treatment
CN105596311A (en) * 2015-12-29 2016-05-25 郑州大明药物科技有限公司 Riociguat oral solid preparation and preparing method thereof
EP3525779B1 (en) 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Combination containing the sgc stimulator vericuguat and the mineralcorticoid receptor antagonist finerenone
CN109890379A (en) 2016-10-11 2019-06-14 拜耳制药股份公司 Combination product comprising sGC activator and mineralocorticoid receptor antagonists
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
EP3609883B1 (en) 2017-04-11 2022-06-29 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
BR112020022340A2 (en) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamides replaced by 1,3-thiazol-2-yl for the treatment of diseases associated with nerve fiber sensitization
EP3820476A1 (en) 2018-07-11 2021-05-19 Cyclerion Therapeutics, Inc. Use of sgc stimulators for the treatment of mitochonrial disorders
TWI830835B (en) * 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE ACTIVE COMPOUND PRODUCT HAVING IMPROVED PROPERTIES, PRODUCTION AND FORMULATION THEREOF
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
CN111689961A (en) * 2020-06-01 2020-09-22 江苏华阳制药有限公司 Novel crystal form of lis ciguat and preparation method thereof
WO2022147183A1 (en) * 2020-12-30 2022-07-07 Jubilant Pharma Holdings Inc. Pharmaceutical extended release suspensions of riociguat

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
DK181190D0 (en) 1990-07-30 1990-07-30 Lundbeck & Co As H 3-ARYL-INDOL OR 3-ARYL-INDAZOL DERIVATIVES
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
ATE216384T1 (en) 1996-01-22 2002-05-15 Fujisawa Pharmaceutical Co THIAZOLYLBENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE19642255A1 (en) 1996-10-14 1998-04-16 Bayer Ag Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives
EE9900151A (en) 1996-10-14 1999-12-15 Bayer Aktiengesellschaft Heterocyclylmethyl-substituted pyrazole derivatives
HU230154B1 (en) 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Process for the preparation of 2-phenyl substituted imidazotriazinones
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834045A1 (en) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl) -1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridine
DE19834047A1 (en) 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19834044A1 (en) 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
DE19846514A1 (en) 1998-10-09 2000-04-20 Bayer Ag New arylmethyl and heterocyclylmethyl substituted heteroaryl-indazole derivatives useful in treatment of cardiovascular, ischemic and urogenital disorders
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
ES2231581T3 (en) 2000-11-22 2005-05-16 Bayer Healthcare Ag NEW DERIVATIVES OF PIRAZOLOPIRIDINE REPLACED WITH LACTAMA.
AR031176A1 (en) 2000-11-22 2003-09-10 Bayer Ag NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE
DE10057751A1 (en) 2000-11-22 2002-05-23 Bayer Ag New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
DE10057754A1 (en) 2000-11-22 2002-05-23 Bayer Ag New cyclic sulfonamido-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
DE10122894A1 (en) 2001-05-11 2002-11-14 Bayer Ag New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
DE10132416A1 (en) 2001-07-04 2003-01-16 Bayer Ag New morpholine-bridged pyrazolopyridine derivatives
US7584505B2 (en) 2001-10-16 2009-09-01 Microsoft Corporation Inspected secure communication protocol
WO2003035005A2 (en) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
WO2003076408A2 (en) 2002-03-08 2003-09-18 Abbott Laboratories Indazole derivatives that are activators of soluble guanylate cyclase
US6738631B1 (en) 2002-05-06 2004-05-18 Nokia, Inc. Vision-guided model-based point-and-click interface for a wireless handheld device
DE10220570A1 (en) 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
DE10222550A1 (en) 2002-05-17 2003-11-27 Bayer Ag New 1-benzyl-3-(2-pyrimidinyl)-pyrazolo-(3,4-b)-pyridine derivatives are soluble guanylate cyclase stimulants, useful e.g. for treating cardiovascular or thromboembolic diseases or sexual dysfunction
DE10232571A1 (en) 2002-07-18 2004-02-05 Bayer Ag 4-amino substituted pyrimidine derivatives
DE10232572A1 (en) 2002-07-18 2004-02-05 Bayer Ag New 2,5-disubstituted pyrimidine derivatives
DE10242941A1 (en) 2002-09-16 2004-03-18 Bayer Ag New 2-(pyrazolo-(3,4-b)-pyridinyl)-5-pyridinyl-4-pyrimidinylamine derivative, is a soluble guanylate cyclase stimulant useful e.g. for treating cardiovascular diseases, hypertension or ischemia
DE10244810A1 (en) 2002-09-26 2004-04-08 Bayer Ag New morpholine-bridged indazole derivatives
CA2530679A1 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
PE20050483A1 (en) 2003-10-31 2005-08-25 Arena Pharm Inc TETRAZOLE DERIVATIVES OF FORMULA (I), ITS PHARMACEUTICAL COMPOSITIONS AND PROCESSES TO PRODUCE PHARMACEUTICAL COMPOSITIONS
CN100355732C (en) 2003-11-03 2007-12-19 上海药明康德新药开发有限公司 Preparation of 2-Cl-5-F-nicotinate and nicotonic acid
DE10351903A1 (en) 2003-11-06 2005-06-09 Bayer Healthcare Ag New combination
GB0403819D0 (en) 2004-02-20 2004-03-24 Merck Sharp & Dohme New compounds
US7514463B2 (en) 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
DE102005020468A1 (en) * 2005-04-29 2006-11-02 Albrecht Bäumer GmbH & Co.KG Machine holding-down clamp for machines on which soft material blocks are machined or cut has bearing elements which are mounted on bars so that they are height-adjustable whereby bearing elements support holding-down clamp frame
DE102006021733A1 (en) 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-tetrazolylindazoles and 3-tetrazolylpyrazolopyridines and their use
DE102006043443A1 (en) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
EP2170884A2 (en) 2007-06-25 2010-04-07 Boehringer Ingelheim International GmbH Chemical compounds
AU2008282156B2 (en) 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
JP2011503185A (en) * 2007-11-13 2011-01-27 テバ ファーマシューティカル インダストリーズ リミティド Polymorphic form of aliskiren hemifumarate and its preparation process
KR20100113542A (en) 2008-01-01 2010-10-21 시플라 리미티드 Method of synthesis of bosentan, its polymorphic forms and its salts
WO2009145814A2 (en) 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
DE102008030206A1 (en) * 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-cyanoalky- and 3-hydroxyalkyl-indoles and their use
DE102008063992A1 (en) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. New aliphatic substituted pyrazolopyridines and their use
DE102009004245A1 (en) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Novel fused, heteroatom-bridged pyrazole and imidazole derivatives and their use
AR077898A1 (en) * 2009-08-26 2011-09-28 Nycomed Gmbh METHYLPIRROLOPIRIMIDINCARBOXAMIDS
PE20121742A1 (en) * 2009-11-27 2012-12-13 Adverio Pharma Gmbh PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINE-2- [1- (2-FLUOROBENZYL) -1H-PIRAZOLO [3,4-b] PYRIDIN-3-IL] PYRIMIDIN-5-IL} METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
UY33040A (en) 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft NEW FORMS POLYMORPHES OF {4,6DIAMINO-2- [1- (2-FLUOROBENCIL-1H-PIRAZOL [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} METHYL CARBAMATE
UY33041A (en) * 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINO-2- [1- (2-FLUOROBENCIL) -1H-PIRAZOLO [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} CARBAMATO DE METTILO AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
RU2012129671A (en) 2009-12-14 2014-01-27 Байер Интеллектуэль Проперти Гмбх NEW METHYL SOLUTIONS (4, 6-DIAMINO-2- [1- (2-Fluorobenzyl) -1H-PYRAZOLO [3, 4-b] PYRIDIN-3-IL] PYRIMIDIN-5-IL) CARBAMATE
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
DE102010021637A1 (en) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituted 5-fluoro-1H-pyrazolopyridines and their use
ME02207B (en) * 2010-05-26 2016-02-20 Adverio Pharma Gmbh THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS
NZ603884A (en) * 2010-05-27 2014-06-27 Merck Sharp & Dohme Soluble guanylate cyclase activators
EA201390060A1 (en) * 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх ANNELED PYRIMIDINES AND TRIAZINES AND THEIR APPLICATION FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES
DE102010040234A1 (en) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Process for the preparation of 5-fluoro-1H-pyrazolo [3,4-b] pyridine-3-carbonitrile
DE102010040233A1 (en) * 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclic aza heterocycles and their use
DE102010043379A1 (en) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use
DE102010043380A1 (en) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituted carbamates and their use
WO2012166390A1 (en) * 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
AU2012300844B2 (en) * 2011-09-02 2017-03-30 Bayer Intellectual Property Gmbh Substituted annellated pyrimidine and the use thereof
CA3040720C (en) 2011-11-25 2021-06-15 Adverio Pharma Gmbh Method for producing substituted 5-fluoro-1h-pyrazolopyridines
DE102012200352A1 (en) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted, fused imidazoles and pyrazoles and their use
CN104327107A (en) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 Preparation method of fluoroquinolone antibiosis medicine
US10414766B2 (en) * 2015-12-15 2019-09-17 Alembic Pharmaceuticals Limited Polymorph of Riociguat and its process for the preparation
EP3574905A1 (en) * 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group

Also Published As

Publication number Publication date
US10087183B2 (en) 2018-10-02
MX2015010725A (en) 2016-05-31
BR112015019571A2 (en) 2017-07-18
JP2016509039A (en) 2016-03-24
EP2958914A1 (en) 2015-12-30
EP3760629A1 (en) 2021-01-06
PE20151590A1 (en) 2015-11-19
AU2014220801A1 (en) 2015-09-10
US20220073515A1 (en) 2022-03-10
CL2015002304A1 (en) 2016-06-03
CR20150422A (en) 2015-12-01
CN105102457A (en) 2015-11-25
PH12015501839A1 (en) 2015-11-09
IL240397A0 (en) 2015-09-24
DOP2015000199A (en) 2015-11-15
AP2015008670A0 (en) 2015-08-31
US20180370970A1 (en) 2018-12-27
US11203593B2 (en) 2021-12-21
US20170334910A1 (en) 2017-11-23
TN2015000361A1 (en) 2017-01-03
US20150376184A1 (en) 2015-12-31
EA201500852A1 (en) 2016-02-29
JP6386478B2 (en) 2018-09-05
CU20150092A7 (en) 2016-03-31
US20200239469A1 (en) 2020-07-30
EP2958914B1 (en) 2020-07-15
CA2901636A1 (en) 2014-08-28
US10662188B2 (en) 2020-05-26
KR20150119871A (en) 2015-10-26
NI201500110A (en) 2016-02-15
WO2014128109A1 (en) 2014-08-28
HK1217488A1 (en) 2017-01-13

Similar Documents

Publication Publication Date Title
HK1217488A1 (en) Forms of methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4- b]pyridino-3-yl]pyrimidino-5-ylmethyl carbamate 4,6--2-[1-(2-)-1h-[3,4-b]-3-]-5-
HK1226394A1 (en) 7 azaindole derivatives
IL241184A0 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
HK1190710A1 (en) Fluoroalkyl-substituted pyrazolopyridines and use thereof
ZA201409299B (en) Risperidone or paliperidone implant formulation
HK1215575A1 (en) Pyrrolopyridine or pyrazolopyridine derivatives
IL251164B (en) Imidazo[4,5-c]pyridine derived ssao inhibitors
ZA201409297B (en) Paliperidone implant formulation
HK1223090A1 (en) 4-azaindole derivatives 4-
EP2970924A4 (en) Phytase formulation
PL3296299T3 (en) Crystal form of 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1h-pyrazol-4-yl)-1h-imidazol-1-yl)-1h-pyrazolo[3,4-b]pyridin-1-yl}benzamide
IL233529A0 (en) 1,5-naphthyridine derivatives and melk inhibitors containing the same
IL251166B (en) Imidazo[4,5-c]pyridine derived ssao inhibitors
HK1208029A1 (en) Imidazopyridine derivatives
HK1214244A1 (en) Imidazopyridine derivatives
TH1501004779A (en) Format of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrasolo[3,4-b]pyridino-3-yl] Pyrimidino-5-yl}methylcarbamate
ITRM20120395A1 (en) DEVICE FOR THE STIMULATION OF PAIRS OF BODIES.